Literature DB >> 29869156

Histology-proven recurrence in the lateral or central neck after systematic neck dissection for medullary thyroid cancer.

Andreas Machens1, Kerstin Lorenz2, Henning Dralle2,3.   

Abstract

PURPOSE: To delineate risk factors for, and examine temporal patterns of, histology-proven recurrent medullary thyroid cancer (MTC) after compartment-oriented surgery.
METHODS: Multivariate Cox regression on overall, node, and soft tissue infiltrate recurrence per previously dissected neck compartment.
RESULTS: Mean follow-up for the 203 (and 158) patients with central (and ipsilateral lateral) neck dissection was 56.1 months. On multivariate Cox regression, tumor size > 20 mm predicted overall and node recurrence in the central neck, whereas extranodal growth predicted overall and node recurrence in the ipsilateral lateral neck. Extrathyroidal extension alone predicted soft tissue infiltrate recurrence in the central neck, and extranodal growth alone soft tissue infiltrate recurrence in the ipsilateral lateral neck. When analyses were restricted to patients not biochemically cured after initial surgery, only extranodal growth predicted overall and node recurrence in the dissected neck compartments.
CONCLUSIONS: Patients not biochemically cured, specifically those with extranodal growth at the initial operation, carry greater risks of node recurrence.

Entities:  

Keywords:  Compartment-oriented neck dissection; Lymph node metastasis; Medullary thyroid carcinoma; Node recurrence; Soft tissue infiltrate recurrence

Mesh:

Year:  2018        PMID: 29869156     DOI: 10.1007/s12020-018-1625-1

Source DB:  PubMed          Journal:  Endocrine        ISSN: 1355-008X            Impact factor:   3.633


  26 in total

1.  Clinical value of 18-fluorine-fluorodihydroxyphenylalanine positron emission tomography/computed tomography in the follow-up of medullary thyroid carcinoma.

Authors:  Markus Luster; Wolfram Karges; Katrin Zeich; Sandra Pauls; Frederik A Verburg; Henning Dralle; Gerhard Glatting; Andreas K Buck; Christoph Solbach; Bernd Neumaier; Sven N Reske; Felix M Mottaghy
Journal:  Thyroid       Date:  2010-05       Impact factor: 6.568

2.  Survival implications of cervical lymphadenectomy in patients with medullary thyroid cancer.

Authors:  Emad Kandil; Marta M Gilson; Haytham H Alabbas; Anthony P Tufaro; Alan Dackiw; Ralph P Tufano
Journal:  Ann Surg Oncol       Date:  2010-10-29       Impact factor: 5.344

3.  Calcitonin and carcinoembryonic antigen doubling times as prognostic factors in medullary thyroid carcinoma: a structured meta-analysis.

Authors:  Johannes A A Meijer; Saskia le Cessie; Wilbert B van den Hout; Job Kievit; Johannes W Schoones; Johannes A Romijn; Johannes W A Smit
Journal:  Clin Endocrinol (Oxf)       Date:  2009-06-26       Impact factor: 3.478

4.  18F-DOPA positron emission tomography for tumour detection in patients with medullary thyroid carcinoma and elevated calcitonin levels.

Authors:  S Hoegerle; C Altehoefer; N Ghanem; I Brink; E Moser; E Nitzsche
Journal:  Eur J Nucl Med       Date:  2001-01

5.  Prognostic impact of serum calcitonin and carcinoembryonic antigen doubling-times in patients with medullary thyroid carcinoma.

Authors:  Jacques Barbet; Loïc Campion; Françoise Kraeber-Bodéré; Jean-François Chatal
Journal:  J Clin Endocrinol Metab       Date:  2005-08-09       Impact factor: 5.958

6.  Biomarker-based risk stratification for previously untreated medullary thyroid cancer.

Authors:  Andreas Machens; Henning Dralle
Journal:  J Clin Endocrinol Metab       Date:  2010-03-25       Impact factor: 5.958

Review 7.  German Association of Endocrine Surgeons practice guideline for the surgical management of malignant thyroid tumors.

Authors:  Henning Dralle; Thomas J Musholt; Jochen Schabram; Thomas Steinmüller; Andreja Frilling; Dietmar Simon; Peter E Goretzki; Bruno Niederle; Christian Scheuba; Thomas Clerici; Michael Hermann; Jochen Kußmann; Kerstin Lorenz; Christoph Nies; Peter Schabram; Arnold Trupka; Andreas Zielke; Wolfram Karges; Markus Luster; Kurt W Schmid; Dirk Vordermark; Hans-Joachim Schmoll; Reinhard Mühlenberg; Otmar Schober; Harald Rimmele; Andreas Machens
Journal:  Langenbecks Arch Surg       Date:  2013-03-03       Impact factor: 3.445

8.  Compartment-oriented microdissection of regional lymph nodes in medullary thyroid carcinoma.

Authors:  H Dralle; I Damm; G F Scheumann; J Kotzerke; E Kupsch; H Geerlings; R Pichlmayr
Journal:  Surg Today       Date:  1994       Impact factor: 2.549

9.  Clinical relevance of 18F-FDG PET and 18F-DOPA PET in recurrent medullary thyroid carcinoma.

Authors:  Hans H G Verbeek; John T M Plukker; Klaas Pieter Koopmans; Jan Willem B de Groot; Robert M W Hofstra; Anneke C Muller Kobold; Anouk N A van der Horst-Schrivers; Adrienne H Brouwers; Thera P Links
Journal:  J Nucl Med       Date:  2012-10-18       Impact factor: 10.057

10.  Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples.

Authors:  R Peto; M C Pike; P Armitage; N E Breslow; D R Cox; S V Howard; N Mantel; K McPherson; J Peto; P G Smith
Journal:  Br J Cancer       Date:  1977-01       Impact factor: 7.640

View more
  1 in total

1.  Construction and Validation of a Prediction Model for Identifying Clinical Risk Factors of Lateral Lymph Node Metastasis in Medullary Thyroid Carcinoma.

Authors:  Yizhou Huang; Yu Min; Gangyi Yang; Hanghang Wang; Guobing Yin; Lili Zhang
Journal:  Int J Gen Med       Date:  2022-03-01
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.